Millennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA)

Millennium Management LLC lessened its holdings in shares of Kamada Ltd. (NASDAQ:KMDA) by 10.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 317,904 shares of the biotechnology company’s stock after selling 36,872 shares during the quarter. Millennium Management LLC owned approximately 0.55% of Kamada worth $1,936,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in shares of Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 1,549 shares during the last quarter. Aristides Capital LLC boosted its position in Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 6,850 shares during the period. NewEdge Advisors LLC increased its holdings in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 8,260 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in shares of Kamada in the fourth quarter valued at about $67,000. Institutional investors own 20.38% of the company’s stock.

Kamada Stock Up 0.7%

NASDAQ KMDA opened at $6.90 on Tuesday. The company has a market capitalization of $396.61 million, a P/E ratio of 24.64, a P/E/G ratio of 0.97 and a beta of 0.94. Kamada Ltd. has a 12-month low of $4.74 and a 12-month high of $9.16. The firm has a 50-day moving average price of $6.57 and a two-hundred day moving average price of $6.67.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.07. The business had revenue of $44.02 million for the quarter, compared to the consensus estimate of $154.06 million. Kamada had a return on equity of 6.30% and a net margin of 9.92%. Equities analysts expect that Kamada Ltd. will post 0.23 EPS for the current year.

Kamada Announces Dividend

The company also recently disclosed a — dividend, which was paid on Monday, April 7th. Investors of record on Monday, March 17th were paid a $0.20 dividend. The ex-dividend date was Monday, March 17th.

Analyst Ratings Changes

KMDA has been the topic of a number of research reports. Benchmark reissued a “buy” rating and issued a $15.00 price target on shares of Kamada in a report on Thursday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Kamada in a research report on Thursday, March 6th. Sidoti raised Kamada to a “hold” rating in a report on Thursday, May 8th. Finally, Wall Street Zen upgraded Kamada from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 21st. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $14.67.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.